Clinical trials: Chemoradiotherapy
Head Cancer Neck
Diffusion MRI for Head and Neck Cancer
The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response.
- Trial name
- NCT04251481
- Testing
- PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- NYU Langone Health
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with oxaliplatin, fluorouracil, and radiation before surgery and alone after surgery in treating patients with locally…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT01561014
- Testing
- erlotinib hydrochloride, oxaliplatin, fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial
The oropharyngeal areas mainly comprises of the tonsil, base tongue (BOT), soft palate and the posterior pharyngeal wall. Traditionally, surgical resection of oropharyngeal cancers (OPC) was a standard procedure, often performed…
- Trial name
- SCOPE (NCT05144100)
- Testing
- Surgery with or without Neck Dissection, Radiation, Cisplatin based chemotherpay
- Where
- India
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Centre
Locally Advanced Lung Carcinoma
Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC
This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for…
- Trial name
- NCT04951063
- Testing
- Hypofractionated radiotherapy, Concurrent chemotherapy, Consolidation immunotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
- Trial name
- NCT03102242
- Testing
- Atezolizumab
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance Foundation Trials, LLC.
Rectal Cancer Patients
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
This study is a single-center, prospective, single-arm, open-label, Phase II clinical trial designed to evaluate the efficacy of radiotherapy combined with CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as neoadjuvant therapy…
- Trial name
- NCT07291401
- Testing
- lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongnan Hospital
Esophageal Squamous Cell Carcinoma
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing…
- Trial name
- NCT06861894
- Testing
- Adebrelimab and nab-paclitaxel and carboplatin, Radiation, standard oesophagectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Zhigang Li
Non-small-cell Lung Cancer
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
- Trial name
- NCT02577341
- Testing
- Nimotuzumab, docetaxel and cisplatin, daily RT to the chest
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma of the Rectum
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
This study combines midostaurin (PKC412) with radiation and a standard chemotherapy drug call 5-Fluorouracil (5-FU) for subjects with advanced rectal cancer.
- Trial name
- NCT01282502
- Testing
- Midostaurin
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Squamous Cell of Head and Neck
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy…
- Trial name
- NCT02585973
- Testing
- AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI)
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI).
- Trial name
- P4-PACIFIC (NCT06634056)
- Testing
- Pentoxifylline, α-Tocopherol
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Rectal Neoplasm Malignant Carcinoma, Chemoradiotherapy
Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Backgrounds: A multicenter randomized phase III trial (NCT02605265) proved that adding irinotecan guided by UGT1A1 to capecitabine-based neoadjuvant chemoradiotherapy significantly increases complete tumor response.
- Conditions
- Rectal Neoplasm Malignant Carcinoma, Chemoradiotherapy, Neoadjuvant Therapy, Predictive Biomarkers
- Trial name
- NCT04227886
- Testing
- Radiation, Capecitabine-Irinotecan Combination
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Diffuse Intrinsic Pontine Glioma
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with…
- Trial name
- NCT04532229
- Testing
- Nimotuzumab+CRT(concurrent IMRT and TMZ)
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Head and Neck Neoplasms, Weight Loss
Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy
72 patients with head and neck cancer, undergoing primary treatment with radiation therapy and concomitant weekly cisplatin, will be recruited to this multicentre trial.
- Trial name
- NCT02557529
- Testing
- Progressive Resistance Training, physical activity, Diet diary
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Herlev Hospital
Rectal Neoplasms
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Although neoadjuvant radiotherapy greatly decreases local recurrence in locally advanced rectal cancer patients undergoing surgery, it inevitably results in short-term and long-term toxicities.
- Trial name
- NCT02288195
- Testing
- Oxaliplatin, capecitabine, Radiation
- Where
- China
- Volunteers
- 663 people
- Sponsor
- Sun Yat-sen University
Pulmonary Hypertension
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
In the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. This damage is characterized by parenchymal damage and vascular damage.
- Trial name
- MRI-HART (NCT02377934)
- Testing
- Cardiac Magnetic Resonance Imaging (MRI)
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- University Medical Center Groningen
Early Low Rectal Cancer
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
TORCH-E2 is a prospective, multicentre, randomized phase II trial. 134 low-lying early (T1-3b/N0-1M0, distance from anal verge ≤5cm) patients will be recruited and assigned to Group 1 and Group 2 (1:1).
- Trial name
- TORCH-E2 (NCT06462053)
- Testing
- Short-course radiotherapy, PD-1 antibody (Toripalimab), Long-course radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
Cancer Stem Cell
Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy
Esophageal cancer is a common and fatal malignancy. It is the eighth most common incident cancer and the sixth leading cause of cancer death in the world.
- Trial name
- NCT02423811
- Testing
- Fursultiamine
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Cheng-Kung University Hospital
Non-Small Cell Lung Cancer Stage, Chemoradiation
Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer
The aim of this study is to evaluate the feasibility and the effect of daily, individual, supervised and structured exercise training before radiotherapy in patients diagnosed with Non-Small Cell Lung Cancer.
- Trial name
- PRIME (NCT03066271)
- Testing
- Exercise +, Control +
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Esophagus Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- T+TP (NCT04177875)
- Testing
- Teripalimab
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.